Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-54861911 in asymptomatic amyloid-positive adults at risk for Alzheimer's dementia
NL-OMON43995Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2016
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of atabecestat in Alzheimer's disease (AD) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change in Preclinical Alzheimer Cognitive Composite score from baseline at Month 54. Started Feb 2016; status: completed.
02
Drugs
atabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON43995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43995.